EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudie

Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India

Sneh Bhargave iD, Vinod Sharma iD, Babita Kataria iD, Atul Batra iD, Deepam Pushpam, Aparna Sharma iD, Raja Pramanik iD, Prabhat S Malik iD, Ranjit K Sahoo iD, Sachin Khurana iD, Vishwajeet Singh, Sameer Bakhshi iD und 3 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go.24.00166 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Sneh Bhargave und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Olanzapine, Vomiting, Carboplatin, Neurokinin-1 Receptor Antagonists. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Prevention of chemotherapy-induced nausea and vomiting with currently recommended NK1 receptor antagonist–based triplet during carboplatin (AUC ≥4) chemotherapy appears inadequate. A comparative study between olanzapine and NK1 receptor antagonist–based combination is lacking. METHODS This was a single-center, phase III, prospective randomized, double-blind, placebo-controlled superiority study comparing olanzapine (olanzapine, ondansetron, dexamethasone [OOD]-experimental arm) with fosaprepitant (fosaprepitant, ondansetron, dexamethasone [FOD]-standard arm) in combination with ondansetron and dexamethasone among chemotherapy-naïve patients (age ≥18 years) receiving carboplatin (AUC ≥4) during the first cycle of single-day chemotherapy. The OOD arm received olanzapine 5 mg per oral once daily (day 1-4), ondansetron 8 mg with dexametahsone 12 mg intravenous (IV) once daily (20 mg with paclitaxel; day 1), and matching placebo for fosaprepitant (day 1). The FOD arm received fosaprepitant 150 mg IV once daily, with the combination (day 1) and matching placebo for olanzapine (days 1-4). The primary outcome was no nausea during the overall period (0-120 hours). RESULTS Between April 2021 and August 2022, a total of 195 patients were evaluable. The proportion of patients without nausea (0 as per Edmonton Symptom Assessment System scale) in OOD versus FOD arms was 44.1% versus 34.4% ( P = .19) in the overall period (0-120 hours). Complete response rates and total control rates were also similar in both arms. One patient had grade 3 sedation in the olanzapine arm. CONCLUSION Olanzapine, in comparison with NK1 antagonist, is not superior for nausea control during carboplatin-induced emesis. It may act as an effective oral alternative for prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OlanzapineVomitingCarboplatinNeurokinin-1 Receptor AntagonistsNauseaAntiemeticsHumansFemaleMaleDouble-Blind MethodMiddle AgedAdultIndiaProspective StudiesAgedOndansetronAntineoplastic AgentsMorpholines

Substanzen

OlanzapineCarboplatinNeurokinin-1 Receptor AntagonistsfosaprepitantAntiemeticsOndansetronAntineoplastic AgentsMorpholines

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, National Cancer Institute, AIIMS- Jhajjar Campus, All India Institute of Medical Sciences, Haryana, India.
  • Department of Geriatrics, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Biostatistics, AIIMS, Nagpur, India.

ORCID-Profile: Sneh Bhargave, Vinod Sharma, Babita Kataria, Atul Batra, Aparna Sharma, Raja Pramanik, Prabhat S Malik, Ranjit K Sahoo, Sachin Khurana, Sameer Bakhshi, Atul Sharma, Lalit Kumar, Akash Kumar

Zitieren

APA

Bhargave, S., Sharma, V., Kataria, B., Batra, A., Pushpam, D., Sharma, A., Pramanik, R., Malik, P. S., Sahoo, R. K., Khurana, S., Singh, V., Bakhshi, S., Sharma, A., Kumar, L., & Kumar, A. (2025). Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. JCO Global Oncology. https://doi.org/10.1200/go.24.00166

Vancouver

Bhargave S, Sharma V, Kataria B, Batra A, Pushpam D, Sharma A, et al. Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. JCO Global Oncology. 2025. doi:10.1200/go.24.00166

BibTeX
@article{Bhargave2025,
  author = {Bhargave, Sneh and Sharma, Vinod and Kataria, Babita and Batra, Atul and Pushpam, Deepam and Sharma, Aparna and Pramanik, Raja and Malik, Prabhat S and Sahoo, Ranjit K and Khurana, Sachin and Singh, Vishwajeet and Bakhshi, Sameer and Sharma, Atul and Kumar, Lalit and Kumar, Akash},
  title = {Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go.24.00166}
}
Kostenlos starten →